Anal adenocarcinoma: resection best within 6 months of CRT

  • Lewis GD & al.
  • Ann Surg Oncol
  • 4 Feb 2019

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with anal adenocarcinoma (AA) who undergo abdominoperineal resection (APR) have better survival if the surgery occurs within 6 months of receiving chemoradiotherapy (CRT) compared with a longer interval.

Why this matters

  • AA is a rare cancer, and there are no evidence-based treatment guidelines for it. This is the largest observational study of the condition to date.

Study design

  • Retrospective analysis of 24,461 patients (95.2% squamous cell carcinoma [AS]; 4.8% AA).
  • Funding: None disclosed.

Key results

  • Median OS was lower in AA vs AS (72.5 vs 143.8 months; P<.001>
  • 96.2% of patients with AA were treated with APR within 6 months of CRT.
  • Patients with AA who underwent APR within 6 months of CRT had a longer median survival than those who had APR ≥6 months after CRT (88.3 vs 58.1 months; P<.001>
  • The

Limitations

  • Retrospective analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit